Shosuke Kita

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)

Naoki Niikura, Takashi Yamanaka, Hironori Nomura et al. · npj Breast Cancer · 2023 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy

Sho Watanabe, Tatsunori Shimoi, Tadaaki Nishikawa et al. · Scientific Reports · 2023 · 19 citations · Full text

Medicine, Hematology, Oncology +15

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy

Shu Yazaki, Tatsunori Shimoi, Masayuki Yoshida et al. · Breast Cancer Research and Treatment · 2022 · 16 citations · Full text

Life Sciences, Immunology, Oncology +16

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai et al. · Frontiers in Oncology · 2023 · 15 citations · Full text

Medicine, Oncology, Breast Oncology +14

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

T. Nakayama, Naoki Niikura, Takashi Yamanaka et al. · Breast Cancer · 2024 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17